Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04156828
Recruitment Status : Recruiting
First Posted : November 8, 2019
Last Update Posted : January 19, 2021
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Bayer
Information provided by (Responsible Party):
University of Washington

Brief Summary:
This phase I trial studies the best dose of copanlisib when given together with combination chemotherapy (R-GCD) in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory) or grade 3b follicular lymphoma that has come back (relapsed) after 1 prior line of therapy. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine, carboplatin, and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving copanlisib together with R-GCD as second line therapy may improve the complete response rate for patients with diffuse large B-cell lymphoma or follicular lymphoma.

Condition or disease Intervention/treatment Phase
Grade 3b Follicular Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Refractory Diffuse Large B-Cell Lymphoma Non-Hodgkin's Lymphoma Drug: Copanlisib Drug: Gemcitabine Drug: Carboplatin Drug: Dexamethasone Biological: Rituximab Biological: Pegfilgrastim Phase 1

Detailed Description:

OUTLINE: This is a dose-escalation study of copanlisib.

Patients receive copanlisib intravenously (IV) and gemcitabine IV on days 1 and 8, carboplatin IV and rituximab IV on day 1, and dexamethasone orally (PO) or IV 30-60 minutes prior to chemotherapy on day 1 or PO in the morning (AM) and 30-60 minutes prior to chemotherapy on days 2-4. Patients also receive pegfilgrastim subcutaneously (SC) on day 8 or 9. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for up to 1 year.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study Evaluating Copanlisib in Combination With R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular Lymphoma
Actual Study Start Date : March 31, 2020
Estimated Primary Completion Date : July 31, 2022
Estimated Study Completion Date : July 31, 2023


Arm Intervention/treatment
Experimental: Treatment (copanlisib, R-GCD)
Patients receive copanlisib IV and gemcitabine IV on days 1 and 8, carboplatin IV and rituximab IV on day 1, and dexamethasone PO or IV 30-60 minutes prior to chemotherapy on day 1 and PO in AM or 30-60 minutes prior to chemotherapy on days 2-4. Patients also receive pegfilgrastim SC on day 8 or 9. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Copanlisib
Given IV
Other Names:
  • 1032568-63-0
  • BAY 80-6946
  • PI3K Inhibitor BAY 80-6946

Drug: Gemcitabine
Given IV
Other Names:
  • dFdCyd
  • Difluorodeoxycytidine
  • 1-(2-Oxo-4-amino-1

Drug: Carboplatin
Given IV
Other Names:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Carboplatinum
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatine
  • Platinwas
  • Ribocarbo

Drug: Dexamethasone
Given PO
Other Names:
  • Aacidexam
  • Adexone
  • Aknichthol Dexa
  • Alba-Dex
  • Alin Depot
  • Auricularum
  • Auxiloson
  • Baycadron
  • Baycuten
  • Cortidexason
  • Cortisumman
  • Decacort
  • Decadrol
  • Decadron
  • Decalix
  • Decameth
  • Decasone
  • Deltafluorene
  • Desameton
  • Dexa-Mamallet
  • Dexafluorene
  • Dexalocal
  • Dexamecortin
  • Dexameth
  • Dexamethasonum
  • Dexamonozon
  • Dexapos
  • Dexinoral
  • Fluorodelta
  • Fortecortin
  • Gammacorten
  • Hexadecadrol
  • Hexadrol
  • Lokalison-F
  • Loverine
  • Methylfluorprednisolone
  • Millicorten
  • Mymethasone
  • Orgadrone
  • Spersadex
  • TaperDex
  • Visumetazone
  • ZoDex

Biological: Rituximab
Given IV
Other Names:
  • 174722-31-7
  • C2B8 Monoclonal Antibody
  • Chimeric Anti-CD20 Antibody
  • MabThera
  • Monoclonal Antibody IDEC-C2B8
  • Rituxan
  • Rituximab ABBS
  • Rituximab Biosimilar ABP 798
  • Rituximab Biosimilar BI 695500
  • Rituximab Biosimilar CT-P10
  • Rituximab Biosimilar GB241
  • rituximab-abbs
  • RTXM83
  • Truxima

Biological: Pegfilgrastim
Given SC
Other Names:
  • 208265-92-3
  • Filgrastim SD-01
  • filgrastim-SD/01
  • Fulphila
  • HSP-130
  • Jinyouli
  • Neulasta
  • Pegfilgrastim Biosimilar HSP-130
  • Pegfilgrastim Biosimilar Pegcyte
  • Pegfilgrastim-jmdb
  • SD-01
  • SD-01 sustained duration G-CSF
  • Nyvepria
  • Pegfilgrastim Biosimilar Udenyca
  • Pegfilgrastim Biosimilar Ziextenzo
  • Udenyca
  • Ziextenzo




Primary Outcome Measures :
  1. Dose limiting toxicity (DLT) [ Time Frame: Up to 21 days ]
    Will assess the presence of a DLT in the first cycle of treatment The dose that estimate of the maximum tolerated dose (MTD) will be obtained using the continuous reassessment method (CRM). Moreover, the proportion of DLT at each dose level will be reported along with the final estimates of the probability of DLT at the MTD based on the CRM along with the 95% confidence interval.


Secondary Outcome Measures :
  1. Complete response rate [ Time Frame: Up to 1 year after 3 cycles of treatment (each cycle is 21 days) ]
    Will be defined by the Lugano Criteria using positron emission tomography (PET)/computed tomography (CT). Will be calculated for patients assigned to the MTD and reported along with an exact binomial 95% confidence interval.

  2. Objective response rate [ Time Frame: Up to 1 year after 3 cycles of treatment (each cycle is 21 days) ]
    Will be defined by the Lugano Criteria using PET/CT. Will be calculated for patients assigned to the MTD and reported along with an exact binomial 95% confidence interval.

  3. Ability to mobilize an adequate number of CD34+ stem cells for autologous stem cell transplant (ASCT) [ Time Frame: Up to 1 year post treatment ]
    For those who initially planned to consolidate treatment with an ASCT, will evaluate the proportion who are able to mobilize an adequate number of CD34+ stem cells for ASCT defined as >= 2 x 10^6 CD34+ cells/kg.

  4. Ability to proceed with ASCT [ Time Frame: Up to 1 year post treatment ]
    Will also evaluate the proportion of patients who initially planned to consolidate treatment with ASCT that are actually able to do so.

  5. Progression free survival (PFS) [ Time Frame: At 1 year ]
    Will also evaluate the 1-year PFS of this population.

  6. Overall survival (OS) [ Time Frame: At 1 year ]
    Will also evaluate the 1-year OS of this population.

  7. Cell of origin (COO) [ Time Frame: Up to 1 year post treatment ]
    Will stratify results based on COO as determined by Hans algorithm or gene expression profiling by nanostring.

  8. Incidence of adverse events [ Time Frame: Up to 28 days after cycle 3 day 1 (each cycle is 21 days) ]
    The National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 will be used to classify and grade toxicities.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must meet one of the following criteria:

    • Histologically confirmed relapsed/refractory DLBCL or grade 3b follicular lymphoma.
    • Follicular lymphoma that has relapsed within 2 years of primary therapy that included an anti-CD20 antibody in combination with chemotherapy as measured from the date of the last dose of chemotherapy
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Previous exposure to other PI3K inhibitors (except copanlisib) is acceptable provided there is no resistance (resistance defined as no response [response defined as partial response (PR) or CR] at any time during therapy), or progressive disease (PD) after any response (PR/CR) or after stable disease within 6 months from the end of the therapy with a PI3K inhibitor
  • Willingness and ability to comply with study and follow-up procedures, and give written informed consent
  • Female subjects of childbearing potential must be surgically sterile, be post-menopausal (per institutional guidelines), or must have a negative pregnancy test within 3 days prior to cycle 1 day 1 and agree to use medically acceptable contraception throughout the study period and for 4 months after the last dose of either study drug. Men of reproductive potential may not participate unless they agree to use medically acceptable contraception throughout the study period and for 4 months after the last dose of either study drug
  • Patients must be expected to receive at least 2 cycles of therapy
  • Patients should have an expected survival if untreated of >= 90 days
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) (< 3 x ULN for patients with Gilbert-Meulengracht syndrome or for patients with cholestasis due to compressive adenopathies of the hepatic hilum) (collected no more than 7 days before starting study treatment)
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement by lymphoma (collected no more than 7 days before starting study treatment)
  • Lipase =< 1.5 x ULN (collected no more than 7 days before starting study treatment)
  • Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 according to the Modification of Diet in Renal Disease (MDRD) abbreviated formula (collected no more than 7 days before starting study treatment). If not on target, this evaluation may be repeated once after at least 24 hours either according to the MDRD abbreviated formula or by 24 hour sampling. If the latter result is within acceptable range, it may be used to fulfill the inclusion criteria instead
  • International normalized ratio (INR) =< 1.5 and partial thromboplastin time (PTT) =< 1.5 x ULN. PT can be used instead of INR if =< 1.5 x ULN (collected no more than 7 days before starting study treatment)
  • Platelet count >= 75,000 /mm^3. For patients with lymphomatous bone marrow infiltration, platelet count >= 50,000 /mm^3 (collected no more than 7 days before starting study treatment)
  • Hemoglobin (Hb) >= 8 g/dl (collected no more than 7 days before starting study treatment). Packed red blood cell transfusion or erythropoietin should not be given less than 7 days before the exam collection
  • Absolute neutrophil count (ANC) >= 1,000/mm^3 (collected no more than 7 days before starting study treatment). For patients with confirmed lymphomatous bone marrow infiltration, ANC count >= 750/mm^3. Myeloid growth factors should not be given less than 7 days before the exam collection

Exclusion Criteria:

  • More than one prior line of therapy for DLBCL
  • More than one prior line of chemoimmunotherapy
  • Prior treatment with copanlisib
  • Documented evidence of resistance to prior treatment with idelalisib or other PI3K inhibitors defined as: No response (response defined as partial response [PR] or complete response [CR]) at any time during therapy, or Progression (PD) after any response (PR/CR) or after stable disease within 6 months from the end of the therapy with a PI3K inhibitor
  • Prior treatment including systemic therapy or radiotherapy within 21 days of study initiation
  • Poorly controlled diabetes mellitus defined as hemoglobin A1c > 8.5%
  • Known lymphomatous involvement of the central nervous system
  • Known history of human immunodeficiency virus (HIV) infection. All patients must be screened for HIV up to 28 days prior to study drug start using a blood test for HIV according to local regulations
  • Hepatitis B (HBV) or C (HCV) infection. All patients must be screened for HBV and HCV up to 28 days prior to study drug start using the routine hepatitis virus laboratorial panel. Patients positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) will be eligible if they are negative for HBV-deoxyribonucleic acid (DNA), these patients should receive prophylactic antiviral therapy. Patients positive for anti-HCV antibody will be eligible if they are negative for HCV-ribonucleic acid (RNA)
  • Previous or concurrent history of malignancies within 3 years prior to study. Any exceptions beyond those listed below must be approved by the principal investigator:

    • Cervical carcinoma in situ
    • Non-melanoma skin cancer
    • Superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria])
    • Localized prostate cancer
  • Active, clinically serious infections (> Common Terminology Criteria for Adverse Events [CTCAE] grade 2)
  • Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation.
  • Proteinuria of >= CTCAE grade 3 as assessed by a 24 hour (h) total urine protein quantification or estimated by urine protein: creatinine ratio > 3.5 on a random urine sample
  • Unresolved toxicity from prior therapy higher than National Cancer Institute (NCI)-CTCAE grade 1 attributed to any prior therapy/procedure excluding alopecia or sensory neuropathy. Concurrent diagnosis of pheochromocytoma
  • Pregnant or breast-feeding patients. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study result
  • Congestive heart failure > New York Heart Association (NYHA) class 2
  • Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
  • Myocardial infarction less than 6 months before start of test drug
  • Uncontrolled arterial hypertension despite optimal medical management (per investigator's assessment)
  • Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before the start of study treatment
  • Non-healing wound, ulcer, or bone fracture
  • Active, clinically serious infections > CTCAE grade 2
  • Patients with seizure disorder requiring medication
  • Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event >= CTCAE grade 3 within 4 weeks prior to the start of study treatment
  • Any illness or medical conditions that are unstable or could jeopardize the safety of the patients and their compliance in the study
  • History of having received an allogeneic bone marrow or organ transplant
  • Anti-arrhythmic therapy (beta blockers or digoxin are permitted)
  • Major surgical procedure or significant traumatic injury (as judged by the investigator) less than 28 days before start of treatment, open biopsy less than 7 days before start of treatment
  • Systemic continuous corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent is not allowed. Patients may be using topical or inhaled corticosteroids. Previous corticosteroid therapy must be stopped or reduced to the allowed dose at least 7 days performing the screening computed tomography (CT)/magnetic resonance imaging (MRI). If a patient is on chronic corticosteroid therapy, corticosteroids should be de-escalated to the maximum allowed dose before the screening. Patients may be using topical or inhaled corticosteroids
  • Use of CYP3A4 inhibitors and inducers. Copanlisib is primarily metabolized by CYP3A4. Therefore, concomitant use of strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and strong inducers of CYP3A4 (e.g., rifampin, phenytoin, carbamazepine, phenobarbital, St. John's wort) are not permitted from day -14 of cycle 1 until the safety follow-up visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04156828


Contacts
Layout table for location contacts
Contact: Ryan Lynch 206.606.1739 rclynch@uw.edu

Locations
Layout table for location information
United States, Washington
Fred Hutch/University of Washington Cancer Consortium Recruiting
Seattle, Washington, United States, 98109
Contact: Ryan Lynch    206-606-1739    rclynch@uw.edu   
Principal Investigator: Ryan Lynch         
Sponsors and Collaborators
University of Washington
National Cancer Institute (NCI)
Bayer
Investigators
Layout table for investigator information
Principal Investigator: Ryan Lynch Fred Hutch/University of Washington Cancer Consortium
Layout table for additonal information
Responsible Party: University of Washington
ClinicalTrials.gov Identifier: NCT04156828    
Other Study ID Numbers: RG1005097
NCI-2019-07286 ( Registry Identifier: NCI / CTRP )
P30CA015704 ( U.S. NIH Grant/Contract )
10332 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium )
First Posted: November 8, 2019    Key Record Dates
Last Update Posted: January 19, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Follicular
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Gemcitabine
Dexamethasone
Dexamethasone acetate
Rituximab
Carboplatin
Antineoplastic Agents, Immunological
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Lenograstim
BB 1101
Immunologic Factors
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Glucocorticoids